Source: Annual Congress 2008 - COPD



Rating:

Share or cite this content

Citations should be made in the following way:
F. Costa, L. Rodrigues, Y. Martins, C. Mendonça (Coimbra, Portugal). Characterization of a population of alpha₁-antitrypsin deficient (A₁ATD) patients. Eur Respir J 2008; 32: Suppl. 52, 4655

Member's Comments

Anafilipa Costa - 08.10.2008 12:04
How was lung function in non-smokers with Pi Null/Null ?
Could you confirm the protective effect of >50 mg/dl A1AT in non-smokers regarding lung function ? Yes, in fact we found that patients with a serum A1AT level below the protective threshhold of 50mg/dl were the ones that had more symptoms and lung function abnormalities together with emphysema detected by CT scan. How was lung function in non-smokers with Pi Null/Null ? Pi Null/Null patients had a moderate obstructive pattern in spirometry (FEV1/FVC 42% and FEV1 58%)and had slight signs of hyperinflation in lung volume mesurements. Addicionaly they had a decreased diffusion capacity, reduced oxygen levels and a slightly widened alveolar-arterial gradient. Could you find/suspect an effect on lung function of occupational exposure in non-smokers ? In theory, patients with SZ and SS genotype, if non-smokers, are expected to have a normal lung function. What we found in our work was that some non-smoking SS and SZ patients with occupational exposure had in fact enphysema and slight lung function abnormalities. From this we can suspect that occupational exposure may have an effect in lung function.

Thierry Rochat - 07.10.2008 11:49
3 questions
Could you confirm the protective effect of >50 mg/dl A1AT in non-smokers regarding lung function ? How was lung function in non-smokers with Pi Null/Null ? Could you find/suspect an effect on lung function of occupational exposure in non-smokers ?

Related content which might interest you: Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD. Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Risk of cancer in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) compared with the Swedish general population Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020 Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006 Comparison between population with severe (ZZ) and intermediate (MZ) alpha1-antitrypsin deficiency and established COPD Source: International Congress 2019 – Advances in clinical management of COPD Year: 2019 Erythrocyte abnormalities in alpha-1-antitrypsin deficiency (AATD) patients Source: Annual Congress 2009 - COPD: exacerbation and clinical problems Year: 2009 Prevalence and phenotype of subjects carrying rare variants in Argentina for alpha1-antitrypsin deficiency Source: International Congress 2017 – Current molecular and genetic understanding of lung diseases Year: 2017 Severe alpha-1-antitrypsin deficiency (A1ATD) caused by Q0Ourém mutation: A clinical characterization Source: Annual Congress 2010 - Genetics of obstruction Year: 2010 Differences of disease phenotypes in individuals with alpha-1-antitrypsin deficiency with genotypes PiZZ and PiSZ - Analysis from the German registry Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Health status changes in alpha-1-antitrypsin deficiency (PiZ phenotype) over 3 years Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD Year: 2003 Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population Year: 2013 Functional alterations of small airways in patients with alpha-1 antitrypsin deficiency (AATD) in a longitudinal study Source: Eur Respir J 2005; 26: Suppl. 49, 361s Year: 2005 Novel genetic variants in alpha-1 antitripsin deficiency cases carrying S alleles and discordant genotype and serum levels Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015 Pulmonary disease in intermediate alpha1-antitrypsin deficient patients Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Effect of danazol on acute phase reactants in patients with PiM, PiMZ and PiZ phenotypes for alpha-1-antitrypsin deficiency Source: Eur Respir J 2001; 18: Suppl. 33, 249s Year: 2001 SERPINA1 gene variants in subjects from a general population with reduced alpha1-antitrypsin level Source: Annual Congress 2008 - COPD Year: 2008 Proteinase 3 activity is present in sputum from subjects with alpha-1-antitrypsin deficiency (AATD) and COPD Source: Annual Congress 2012 - The smoking gun in COPD biology Year: 2012 Frequency of α-1 antitrypsin deficiency (AATD) in a population screening in an high risk area (Val Trompia, Italy) Source: Eur Respir J 2006; 28: Suppl. 50, 453s Year: 2006 Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD). Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases Year: 2021 Tracing down the evolutionary history of Q0Ourém, a rare allele associated with severe alpha-1-antitrypsin deficiency (AATD) Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 Clinical phenotype of individuals with common COPD investigated during the targeted detection programme for alpha1-antitrypsin deficiency in Italy Source: Annual Congress 2007 - Clinical aspects in COPD Year: 2007